Overall, our findings confirm that tumor biology—particularly proliferation index and hormone receptor status—was the main determinant of therapeutic decisions, underscoring the importance of reassessing biomarkers after surgery and reinforcing the paradigm of individualized, biology-driven treatment in breast cancer. This evidence concerns the gene NR4A1 and breast cancer.